Anti-PD1 in the wonder-gut-land

After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 th...

Full description

Saved in:
Bibliographic Details
Published in:Cell research 2018-03, Vol.28 (3), p.263-264
Main Authors: Vetizou, Marie, Trinchieri, Giorgio
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Cancer
Cancer immunotherapy
Cell Biology
Immune checkpoint
Immune system
Immunotherapy
Intestinal microflora
Life Sciences
Melanoma
Microbiota
Patients
PD-1 protein
Research Highlight
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.
ISSN:1001-0602
1748-7838
DOI:10.1038/cr.2018.12